BBIO Fundamental Analysis - BRIDGEBIO PHARMA INC

Name: BRIDGEBIO PHARMA INC (BBIO) Stock
Brand: BRIDGEBIO PHARMA INC
Rating: 7 (3 reviews)

Fundamental Rating

Overall BBIO gets a fundamental rating of 3 out of 10. We evaluated BBIO against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of BBIO have multiple concerns. BBIO shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

BBIO had negative earnings in the past year.

In the past year BBIO has reported a negative cash flow from operations.

BBIO had negative earnings in each of the past 5 years.

In the past 5 years BBIO always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -79.85%, BBIO is doing worse than 67.54% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-79.85%
ROE	N/A
ROIC	N/A

ROA(3y)-84.41%

ROA(5y)-74.51%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 95.78%, BBIO belongs to the top of the industry, outperforming 94.93% of the companies in the same industry.

BBIO's Gross Margin has been stable in the last couple of years.

BBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.78%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.94%

GM growth 5Y0.92%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.

BBIO has more shares outstanding than it did 1 year ago.

BBIO has more shares outstanding than it did 5 years ago.

BBIO has a better debt/assets ratio than last year.

2.2 Solvency

BBIO has an Altman-Z score of -3.33. This is a bad value and indicates that BBIO is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -3.33, BBIO is in line with its industry, outperforming 45.97% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-3.33

ROIC/WACCN/A

WACC8.42%

2.3 Liquidity

A Current Ratio of 3.88 indicates that BBIO has no problem at all paying its short term obligations.

BBIO has a Current ratio (3.88) which is in line with its industry peers.

A Quick Ratio of 3.76 indicates that BBIO has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.76, BBIO is in line with its industry, outperforming 47.65% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.88
Quick Ratio	3.76

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BBIO have decreased strongly by -57.74% in the last year.

Looking at the last year, BBIO shows a very strong growth in Revenue. The Revenue has grown by 62.46%.

Measured over the past years, BBIO shows a very strong growth in Revenue. The Revenue has been growing by 40.48% on average per year.

EPS 1Y (TTM)-57.74%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%13.64%

Revenue 1Y (TTM)62.46%

Revenue growth 3Y47.1%

Revenue growth 5Y40.48%

Sales Q2Q%4318.01%

3.2 Future

Based on estimates for the next years, BBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 33.87% on average per year.

Based on estimates for the next years, BBIO will show a very strong growth in Revenue. The Revenue will grow by 68.42% on average per year.

EPS Next Y-15.03%

EPS Next 2Y16.6%

EPS Next 3Y25.38%

EPS Next 5Y33.87%

Revenue Next Year121.3%

Revenue Next 2Y95.92%

Revenue Next 3Y84.83%

Revenue Next 5Y68.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBIO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BBIO's earnings are expected to grow with 25.38% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.6%

EPS Next 3Y25.38%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BBIO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (11/18/2025, 7:33:34 PM)

After market: 65.59 0 (0%)

65.59

-1.31 (-1.96%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-29 2025-10-29/amc

Earnings (Next)02-18 2026-02-18/amc

Inst Owners91.27%

Inst Owner Change-4.47%

Ins Owners4.15%

Ins Owner Change-14.46%

Market Cap12.54B

Revenue(TTM)353.78M

Net Income(TTM)-797.12M

Analysts84

Price Target71.13 (8.45%)

Short Float %11.86%

Short Ratio8.31

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-7.62%

Min EPS beat(2)-10.44%

Max EPS beat(2)-4.81%

EPS beat(4)1

Avg EPS beat(4)-7.51%

Min EPS beat(4)-21.38%

Max EPS beat(4)6.56%

EPS beat(8)3

Avg EPS beat(8)11.85%

EPS beat(12)3

Avg EPS beat(12)2.94%

EPS beat(16)5

Avg EPS beat(16)7.09%

Revenue beat(2)2

Avg Revenue beat(2)14.91%

Min Revenue beat(2)11.23%

Max Revenue beat(2)18.58%

Revenue beat(4)4

Avg Revenue beat(4)45.04%

Min Revenue beat(4)11.23%

Max Revenue beat(4)84.61%

Revenue beat(8)5

Avg Revenue beat(8)176.66%

Revenue beat(12)5

Avg Revenue beat(12)105%

Revenue beat(16)6

Avg Revenue beat(16)88%

PT rev (1m)3.17%

PT rev (3m)11.04%

EPS NQ rev (1m)8.54%

EPS NQ rev (3m)8.45%

EPS NY rev (1m)-2.96%

EPS NY rev (3m)-10.55%

Revenue NQ rev (1m)16.03%

Revenue NQ rev (3m)15.82%

Revenue NY rev (1m)3.65%

Revenue NY rev (3m)8.24%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	35.44
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-4.18

EYN/A

EPS(NY)-1.98

Fwd EYN/A

FCF(TTM)-3.13

FCFYN/A

OCF(TTM)-3.06

OCFYN/A

SpS1.85

BVpS-10.11

TBVpS-10.26

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-79.85%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	95.78%
FCFM	N/A

ROA(3y)-84.41%

ROA(5y)-74.51%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.94%

GM growth 5Y0.92%

F-Score4

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	238.46%
Cap/Sales	3.62%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.88
Quick Ratio	3.76
Altman-Z	-3.33

F-Score4

WACC8.42%

ROIC/WACCN/A

Cap/Depr(3y)86.7%

Cap/Depr(5y)N/A

Cap/Sales(3y)8.73%

Cap/Sales(5y)27.27%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-57.74%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%13.64%

EPS Next Y-15.03%

EPS Next 2Y16.6%

EPS Next 3Y25.38%

EPS Next 5Y33.87%

Revenue 1Y (TTM)62.46%

Revenue growth 3Y47.1%

Revenue growth 5Y40.48%

Sales Q2Q%4318.01%

Revenue Next Year121.3%

Revenue Next 2Y95.92%

Revenue Next 3Y84.83%

Revenue Next 5Y68.42%

EBIT growth 1Y-11.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year19%

EBIT Next 3Y28.25%

EBIT Next 5Y24.11%

FCF growth 1Y-20.05%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-17.87%

OCF growth 3YN/A

OCF growth 5YN/A

BRIDGEBIO PHARMA INC / BBIO FAQ

What is the fundamental rating for BBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to BBIO.

What is the valuation status of BRIDGEBIO PHARMA INC (BBIO) stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIDGEBIO PHARMA INC (BBIO). This can be considered as Overvalued.

Can you provide the profitability details for BRIDGEBIO PHARMA INC?

BRIDGEBIO PHARMA INC (BBIO) has a profitability rating of 1 / 10.

What is the earnings growth outlook for BRIDGEBIO PHARMA INC?

The Earnings per Share (EPS) of BRIDGEBIO PHARMA INC (BBIO) is expected to decline by -15.03% in the next year.

BRIDGEBIO PHARMA INC (BBIO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BRIDGEBIO PHARMA INC / BBIO FAQ

What is the fundamental rating for BBIO stock?

What is the valuation status of BRIDGEBIO PHARMA INC (BBIO) stock?

Can you provide the profitability details for BRIDGEBIO PHARMA INC?

What is the earnings growth outlook for BRIDGEBIO PHARMA INC?